Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
30 Cards in this Set
- Front
- Back
|
What are the erythropoetin drug agents?
What are their dosing rates? |
Epoetin alpha
(3 doses/week) Darbepoetin alpha (1 dose/week) Epoetin Beta (1-2 doses/month) |
|
|
MOA of erythropoetin agents?
|
Bind to erythropoetin receptor (on RBC progenitors), which stimulate the JAK/STAT pathway.
(JAK/STAT = Janice Kinase Signal Transducer and activator of Transcription Pathway) |
|
|
Adverse effect(s) of erythropoetin agents include?
|
Hypertension
Thrombotic complications |
|
|
Uses of erythropoetin agents? (4)
|
1) Improve Hct levels
2) Eliminate need for transfusions 3) Treat anemia secondary to chronic renal failure (caution, AE renal failure problem) (Note: most pts require Fe and Folate supplementation to support increased erythropoiesis) 4) Treat anemia due to Primary Bone Marrow disorders and Secondary anemias --> AZT tx --> myelosuppression |
|
|
What are the myeloid growth factors?
|
Filgrastim
Pegfilgrastim Sargramostim |
|
|
G-CSF (granulocyte colony stimulating factor) is associated with what hematopoetic drug?
|
Filgrastim and Pegfilgrastim
|
|
|
GM-CSF as a drug, is?
|
Sargramostim
...a recombinant human protein |
|
|
MOA of meyloid growth factors?
|
G-CSF binds to G-CSF receptors on surface of myeloid progintor cells, and stimulate JAK/STAT pathway.
(same thing for GM-CSF, but bind/stimulate GM-CSF receptors). |
|
|
Myeloid growth factors are used to treat?
|
Neutropenias (different types)
(along with Pancytopenia?) |
|
|
Filgrastim is produced where?
|
In bacterial system...
Why? It does not require glycosylation. |
|
|
How are filgrastim and pegfilgrastim administered?
|
Parenterally
|
|
|
Where is sargramostim produced?
|
In yeast system...
Why? It needs to be glycosylated. |
|
|
What has a longer half life, Filgrastim or Pegfilgrastim?
|
Pegfilgrastim
|
|
|
What is/are the adverse effect(s) of myeloid growth factors?
|
Bone pain (throbbing)
Leukocytosis Hyperurecemia Splenic rupture Capillary leak syndrome/Pleural or pericardial effusions |
|
|
What does sargrastim stimulate?
|
Stimulates early and late granulocytic progenitor cells (erythroid and megakaryocytes)
|
|
|
Use of Sargramostim?
|
Decrease duration of neutropenia following chemotherapy.
|
|
|
Megakaryocyte growth factors include?
|
Oprelvekin
Romiplostim Eltrombopag |
|
|
Human recombinant IL-11, but produced in E.coli....This is what drug?
|
Oprelvekin
|
|
|
How is oprelvekin administered?
It's half life? |
Subcutaneously
7-8 hours |
|
|
What does oprelvekin stimulate, and how?
|
Stimulates growth of megakaryocyte progenitors by activating the JAK/STAT pathway.
|
|
|
Of the megakaryocytes, oprelvekin used for?
|
Chemotherapy-induced thromocytopenia
(but only in cases of non-myeloid cancers, aka cancers arising from white blood cells) |
|
|
Megakaryocyte growth factors typically increase/decrease platelet counts in patients?
|
Increase
|
|
|
Thrombopoietin receptor agonist (aka Mp1 agonists) include?
|
Romiplostim
Eltrombopag |
|
|
Romiplostim is used to treat?
|
Idiopathic thrombocytopenia Purpura (ITP)
|
|
|
Romiplostim route of administration is?
Half life? |
Subcutaneous administration.
3-4 days. |
|
|
This megakaryocyte growth factor has a dose-dependent increase in platelet count.
|
Romiplostim
|
|
|
Eltrombopag is administered how?
|
PO (per oral)
|
|
|
Eltrombopag is used to treat?
|
Idiopathic Thrombocytopenia Purpura (ITP) in patients who are unresponsive to standard therapies (or unable to take them).
|
|
|
Romiplostim's adverse effect(s)?
|
Sometimes will increase a biomarker for a cancer.
|
|
|
This megakaryocyte growth factor use is highly regulated...
|
Eltrombopag
|
